Cytek Biosciences (CTKB) FCF Margin (2020 - 2026)
Cytek Biosciences (CTKB) posted FCF Margin of 11.11% for Q1 2026, down 416.29% on a QoQ basis from 3.51% in Q4 2025, and down 1025.0% year-over-year from 1.2% in Q1 2025.
Cytek Biosciences (CTKB) FCF Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences' FCF Margin history runs 7 years deep, the most recent figure standing at 11.11% for Q1 2026.
- Quarterly FCF Margin fell 1025.0% year-over-year to 11.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.58% (down 1547.0% YoY) and the FY2025 annual result came in at 2.39%, down 1496.0% from the prior year.
- FCF Margin was 11.11% for Q1 2026 at Cytek Biosciences, down from 3.51% in the prior quarter.
- Across five years, FCF Margin topped out at 28.63% in Q3 2024 and bottomed at 28.19% in Q2 2022.
- A 5-year average of 1.02% and a median of 0.7% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin surged 4395 bps — and 2025, when it plunged 4190 bps.
- Cytek Biosciences' FCF Margin stood at 0.7% in 2022, then surged by 3208 bps to 21.67% in 2023, then plunged by 85 bps to 3.34% in 2024, then advanced by 5 bps to 3.51% in 2025, then sank by 416 bps to 11.11% in 2026.
- Business Quant data shows CTKB's FCF Margin at 11.11% in Q1 2026, 3.51% in Q4 2025, and 13.27% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | -11.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.11% |
| Dec 31, 2025 | 3.51% |
| Sep 30, 2025 | -13.27% |
| Jun 30, 2025 | 0.66% |
| Mar 31, 2025 | -0.87% |
| Dec 31, 2024 | 3.34% |
| Sep 30, 2024 | 28.63% |
| Jun 30, 2024 | 11.05% |
| Mar 31, 2024 | 7.56% |
| Dec 31, 2023 | 21.67% |
| Sep 30, 2023 | -15.33% |
| Jun 30, 2023 | -5.52% |
| Mar 31, 2023 | 7.33% |
| Dec 31, 2022 | -0.70% |
| Sep 30, 2022 | -21.28% |
| Jun 30, 2022 | -28.19% |
| Mar 31, 2022 | -4.87% |
| Dec 31, 2021 | 10.68% |
| Sep 30, 2021 | -4.56% |
| Jun 30, 2021 | -12.31% |